The impact of influenza vaccination is largely measured by estimating vaccine effectiveness (VE), which vary in different seasons. Strain mutations and waning immunity present two key mechanisms affecting VE. We sought to quantify the relative effect of these mechanisms by projecting VE and the reduction of illness due to vaccination. We developed a stochastic age-structured agent-based simulation model of influenza transmission dynamics to encapsulate intraseason waning of immunity post-vaccination, and mutation-induced antigenic distance between circulating strains and vaccine strains. Parameterizing the model with published estimates, we projected the temporal and overall VE during an epidemic season, and estimated the reduction of infec...
Influenza epidemics annually cause substantial morbidity and mortality. For this reason, vaccination...
For infectious disease prevention, policy-makers are typically required to base policy decisions in ...
Limited production capacity and delays inherent in vaccine development are major hurdles to the wide...
For most pathogens, vaccination reduces the spread of the infection and total number of cases; thus,...
Influenza epidemic dynamics are impacted by many factors including transmissibility of the circulati...
Abstract Background Protective antibody immunity against the influenza A virus wanes in 2–7 years du...
For most pathogens, vaccination reduces the spread of the infection and total number of cases; thus,...
The success of a seasonal influenza vaccine efficacy trial depends not only upon the design but also...
Influenza is an infectious seasonal disease against which yearly vaccination is recommended, especia...
In this study, we simulate an influenza epidemic that considers the effects of waning immunity by fi...
Introduction: Current influenza vaccines have limited effectiveness. COVID-19 vaccines using mRNA te...
Developing accurate and reliable methods to estimate vaccine protection is a key goal in immunology ...
Abstract Background After vaccination, vaccinees acquire some protection against infection and/or di...
Influenza vaccine policies that maximise health benefit through efficient use of limited resources a...
With influenza vaccination rates in the United States recently exceeding 45% of the population, it i...
Influenza epidemics annually cause substantial morbidity and mortality. For this reason, vaccination...
For infectious disease prevention, policy-makers are typically required to base policy decisions in ...
Limited production capacity and delays inherent in vaccine development are major hurdles to the wide...
For most pathogens, vaccination reduces the spread of the infection and total number of cases; thus,...
Influenza epidemic dynamics are impacted by many factors including transmissibility of the circulati...
Abstract Background Protective antibody immunity against the influenza A virus wanes in 2–7 years du...
For most pathogens, vaccination reduces the spread of the infection and total number of cases; thus,...
The success of a seasonal influenza vaccine efficacy trial depends not only upon the design but also...
Influenza is an infectious seasonal disease against which yearly vaccination is recommended, especia...
In this study, we simulate an influenza epidemic that considers the effects of waning immunity by fi...
Introduction: Current influenza vaccines have limited effectiveness. COVID-19 vaccines using mRNA te...
Developing accurate and reliable methods to estimate vaccine protection is a key goal in immunology ...
Abstract Background After vaccination, vaccinees acquire some protection against infection and/or di...
Influenza vaccine policies that maximise health benefit through efficient use of limited resources a...
With influenza vaccination rates in the United States recently exceeding 45% of the population, it i...
Influenza epidemics annually cause substantial morbidity and mortality. For this reason, vaccination...
For infectious disease prevention, policy-makers are typically required to base policy decisions in ...
Limited production capacity and delays inherent in vaccine development are major hurdles to the wide...